The effects of beta blockers on long-term morbidity and mortality have been established in patients with chronic heart failure with reduced left ventricular function. Among various beta blockers, only carvedilol and bisoprolol are approved by Japanese guidelines for treatment of patients with chronic heart failure. Bisoprolol is highly selectivity for the beta-1 receptor, while carvedilol is a non-selective beta blocker with simultaneous alpha receptor antagonist effects. BNP and NT-proBNP are established biomarkers used in the diagnosis and prognosis of chronic heart failure. Recently, hsTnT, which is released by injured myocardial tissue, has also been investigated as a marker of heart failure. Although several reports have compared bisoprolol and carvedilol in patients with chronic heart failure in Japan as well as in western countries, these reports did not focus on hsTnT levels. We thus designed the “Bisoprolol Improvement Group for chronic heart failure treatment study in Dokkyo Medical University” (BRIGHT-D) to directly compare drug tolerability, heart failure symptoms, biomarkers and cardiac function between bisoprolol and carvedilol in patients with chronic heart failure with reduced ejection fraction. As a result, bisoprolol might have some potential advantage over carvedilol in terms of protection against myocardial injury. In this session, we would like to present and discuss our data.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect